Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
29 May 2024 - 9:00PM
Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage
company developing transformational treatments for patients with
serious metabolic diseases marked by high unmet medical need, today
announced that management will present at the Jefferies Global
Healthcare Conference on Wednesday, June 5, 2024, at 4:00 p.m. E.T.
in New York, NY.
A live webcast of the Company presentation will be
available through the investor relations section of the Company's
website at www.akerotx.com. Following the live webcast, an
archived replay will be available on the Company's website.
About Akero TherapeuticsAkero
Therapeutics is a clinical-stage company developing
transformational treatments for patients with serious metabolic
diseases marked by high unmet medical need, including MASH. Akero's
lead product candidate, EFX, is currently being evaluated in the
ongoing SYMMETRY study, a 96-week Phase 2b clinical trial in
patients with compensated cirrhosis due to MASH (F4 fibrosis), as
well as two ongoing Phase 3 clinical trials: the
SYNCHRONY Histology study in patients with pre-cirrhotic
MASH (F2-F3 fibrosis) and the SYNCHRONY Real-World study
in patients with MASH (F1-F3 fibrosis) or MASLD. A third clinical
trial, the SYNCHRONY Outcomes study in patients with
compensated cirrhosis due to MASH (F4 fibrosis), is expected to be
initiated in the second quarter of 2024. The Phase 3 SYNCHRONY
program builds on the results of two Phase 2b clinical trials, the
HARMONY study in patients with pre-cirrhotic MASH (F2-F3) and the
SYMMETRY study in patients with compensated cirrhosis due to MASH
(F4). Akero is headquartered in South San Francisco. Visit us
at akerotx.com and follow us
on LinkedIn and X for more information.
Investor Contact:Christina
TartagliaPrecision
AQ212.362.1200christina.tartaglia@precisionaq.com
Media Contact:Sarah
O’Connell732.456.0092soconnell@vergescientific.com
Akero Therapeutics (NASDAQ:AKRO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Akero Therapeutics (NASDAQ:AKRO)
Historical Stock Chart
From Jul 2023 to Jul 2024